Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis-Reference-Cited by-同舟云学术

Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis

Published:2024-05 Issue:5 Volume:30 Page:1349-1362
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Thomas Molly Fisher^ORCID,Slowikowski Kamil^ORCID,Manakongtreecheep Kasidet,Sen Pritha,Samanta Nandini,Tantivit Jessica^ORCID,Nasrallah Mazen,Zubiri Leyre,Smith Neal P.^ORCID,Tirard Alice,Ramesh Swetha^ORCID,Arnold Benjamin Y.,Nieman Linda T.,Chen Jonathan H.,Eisenhaure Thomas,Pelka Karin^ORCID,Song Yuhui^ORCID,Xu Katherine H.,Jorgji Vjola,Pinto Christopher J.,Sharova Tatyana,Glasser Rachel,Chan PuiYee,Sullivan Ryan J.^ORCID,Khalili Hamed^ORCID,Juric Dejan^ORCID,Boland Genevieve M.^ORCID,Dougan Michael,Hacohen Nir^ORCID,Li Bo,Reynolds Kerry L.,Villani Alexandra-Chloé^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

Damon Runyon Cancer Research Foundation

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-02895-x.pdf

Reference93 articles.

1. Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

2. Arnaud-Coffin, P. et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int. J. Cancer 145, 639–648 (2019).

3. Chen, J. H., Pezhouh, M. K., Lauwers, G. Y. & Masia, R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am. J. Surg. Pathol. 41, 643–654 (2017).

4. Verschuren, E. C. et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin. Gastroenterol. Hepatol. 14, 836–842 (2016).

5. Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275–4280 (2010).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting IL-17A to combat immune-related adverse events;Nature Cancer;2024-08-29